search

Active clinical trials for "Hypertension, Malignant"

Results 1-10 of 11

Interrupters of VAscular daMAge in Malignant Hypertension

Malignant Hypertension

The pathophysiology of malignant hypertension is poorly understood. The objective of this translational research project is to evaluate the relationship between activation of vasoactive systems (renin-angiotensin and endothelin systems), angiogenic signal deficiency (VEGF and sFlt-1) and the occurrence of malignant hypertension episodes in humans.

Recruiting19 enrollment criteria

a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency...

Hypertensive Emergency

A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the efficacy and safety of QLG2071 Versus Cleviprex® in the Treatment of Hypertensive Emergency and Sub-emergency

Not yet recruiting14 enrollment criteria

A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and...

Hypertensive Emergency

A randomized, double-blind, active-compared phase Ш clinical trial to evaluate clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency.

Not yet recruiting20 enrollment criteria

Postpartum Hypertension Study

Postpartum Pregnancy-Induced HypertensionPostpartum Preeclampsia2 more

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Not yet recruiting5 enrollment criteria

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Hemolytic and uremic syndrome (HUS) is a clinic-biological syndrome related to thrombotic microangiopathy affecting predominantly the kidney. Atypical HUS (aHUS) has been historically defined as HUS occurring in the absence of infectious event. The role of complement dysregulation in aHUS pathophysiology has been largely demonstrated, since C genetic rare variants are present in 60-70% aHUS patients. In line with the frequency of C dysregulation in aHUS, Eculizumab, an anti-C5 monoclonal antibody, has dramatically improved aHUS patients prognosis. Numerous conditions have been associated with aHUS, including hypertensive emergency (HE), a syndrome of acute blood pressure flare associated with end-organ damage. In cases of HE-aHUS, whether primary aHUS is complicated by secondary HE, or primary HE leads to secondary aHUS is still debated. The investigators recently demonstrated that C genetic variants frequency was similar in patients with HE-aHUS and patients with aHUS without HE, suggesting a major role for C dysregulation in HE-aHUS. Consequently, the investigators propose to evaluate, in HE-aHUS patients, the benefit of a strategy with early Eculizumab therapy (used within its marketing authorization and its conditions of refunding by the health insurance in usual care), compared to standard of care including tight blood pressure control. The hypothesis suggests that C dysregulation may impact renal prognosis of HE-aHUS patients. The investigator's aim to demonstrate that early Eculizumab therapy improves prognosis of HE-aHUS patients. Method The HYPERSHU study is a randomized, controlled, open-labelled study including HE-aHUS patients with severe AKI and no evidence of other conditions associated with HUS (infections, autoimmunity, drugs, pregnancy). The investigators plan to include 62 patients. Patients will be randomized in 2 arms: Early Eculizumab therapy (for 3 months) added to standard of care (tight blood pressure control). Standard of care alone with tight blood pressure control. Renal function after 6 months is the primary evaluation criterium. HE is a frequently associated with aHUS, and strongly impacts patient renal prognosis. Efficient therapeutic strategies are still lacking for this condition. The HYPERSHU study will allow to evaluate the benefit of early Eculizumab therapy in patients with HE-aHUS and severe renal dysfunction.

Not yet recruiting27 enrollment criteria

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

Malignant Hypertension

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Recruiting5 enrollment criteria

Single Incision Laparoscopy

AppendicitisCholelithiasis1 more

Laparoscopic surgery being performed with only one small incision via the umbilicus (belly button).

Completed17 enrollment criteria

Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and...

Hypertensive Emergency

Emergency treatment warning of clevidipine butyrate butyrate injection or invalid medical treatment and verification of the effectiveness and safety of subacute.

Unknown status15 enrollment criteria

Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

Hypertensive Emergency

The purpose of this study was to determine the efficacy and safety of clevidipine for treating Hypertensive emergencies(defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >120 mmHg, accompanied by acute organ damage).

Unknown status18 enrollment criteria

Using Ambu Aura-i Laryngeal Mask Airway in Cranial Surgery

HypertensionMalignant1 more

the investigators hypothesize that Ambu aura-i LMA can be used safely in patients undergoing craniotomies and are effective in reducing the incidence of emergence hypertension.

Completed8 enrollment criteria
12

Need Help? Contact our team!


We'll reach out to this number within 24 hrs